December 10, 2020: We need longer-term data on the Pfizer COVID-19 vaccine to fully understand if benefits outweigh the risks for frail patients and all races/ethnicities, and for everyone else as well. It is essential that FDA ensure the continuation of the randomized controlled trial.
Read More »On Medical Treatments & Products
Public Comments Regarding ACIP Meeting on December 1, 2020
December 1, 2020: We are concerned about the lack of data on the vaccines in patients living in long-term care facilities, or any patients over 65 years of age.
Read More »NCHR’s Comments on Drug Labeling for Geriatric Patients
November 16, 2020: We agree that the FDA should immediately develop clear guidelines for labeling that addresses safety and effectiveness of drugs in the geriatric population.
Read More »NCHR Statement at FDA Alzheimer’s Advisory Committee Meeting On Aducanumab
November 6, 2020: Aducanumab could be promising, but we need better evidence before approving it.
Read More »NCHR’s Testimony at FDA Meeting for Reducer Circulatory System Device
October 27, 2020: The data provided thus far simply do not provide enough evidence that there are benefits outweighing the risks for the Reducer, a permanent device.
Read More »